Publication
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Authors not recorded
Breast Cancer Res2017PMID 28183331PMC5301372stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugDovitinibcivic_curation1.00
- geneFGFR1civic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28183331
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR1 Amplification1 | ||||||||
| Dovitinib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12478Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC) PMID 28183331 · Musolino et al., 2017 · Open in CIViC | civic |